

Biome Australia Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Biome Australia Limited
ABN:	51 627 364 014
Reporting period:	For the half-year ended 31 December 2021
Previous period:	For the half-year ended 31 December 2020

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	98.2% to	1,802,611
Loss from ordinary activities after tax attributable to the owners of Biome Australia Limited	down	25.2% to	(2,479,914)
Loss for the half-year attributable to the owners of Biome Australia Limited	down	25.2% to	(2,479,914)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$2,479,914 (31 December 2020: \$3,314,622).

Financial Performance

During the half year period, the Company experienced strong sales growth with revenue increasing by 98.2% to \$1,802,611 compared to the previous corresponding period (1H21 \$909,561). The strong sales growth has been driven primarily by Biome's Activated Probiotics, live biotherapeutics (probiotics).

Retail pharmacy partner, Terry White Chemmart and pharmacy wholesaler Symbion, both reported that Biome's Activated Probiotics is the number one growth brand in the professional vitamin category within their networks for the 12 months to October 2021. The sales trajectory has also benefitted from the progressive easing of the COVID-19 lockdown restrictions throughout Australia and the consequential return of active field sales.

The loss for the consolidated entity after providing for income tax amounted to \$2,479,914 (31 December 2020: \$3,314,622). Sales and marketing costs increased by \$142,152 to \$1,879,668 as a result of increased expenditure on promoting the Company's products.

During the half year the Company strengthened its product portfolio through the launch of Biome Eczema Probiotic and Biome Her Probiotic, opening up new patient customer segments. Feedback from customers (health professionals) has been favourable, reporting positive patient outcomes and improvements in both mild eczema and female genitourinary health concerns following use of Biome Eczema Probiotic and Biome Her Probiotic, respectively.

Biome's largest distribution channel continues to be community pharmacy. Recent launches into the health food and practitioner channels with distributors, Osborne Health, Renner Health, Ariya and Vital.ly have supported growth in this new channel. Independent health practitioners now represent more than 20% of Biome's total sales.

Financial Position

During the financial year, the Company raised \$8 million before capital raising costs through an initial public offering and had \$7,743,968 in cash as at 31 December 2021.

The net assets of the Company increased by \$7,005,585 from June 2021 to \$8,585,713 as at 31 December 2021 which was a result of the Company's IPO and capital raising.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	4.29	0.52

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Biome Australia Limited for the half-year ended 31 December 2021 is attached.

12. Signed

Signed _____

Mr Ilario Faenza
Chairman

Date: 25 February 2022

Biome Australia Limited

ABN 51 627 364 014

Interim Report - 31 December 2021

Biome Australia Limited
Corporate directory
31 December 2021

Directors	Blair William Brabin Vega Norfolk (Managing Director) Ilario Thomas Faenza (Non-Executive Director) Dominique Gayle Fisher (Independent Non-Executive Director)
Company secretary	George Lazarou
Registered office	16 Dover Street Cremorne Victoria 3121
Principal place of business	16 Dover Street Cremorne Victoria 3121
Share register	Automic Pty Ltd
Auditor	JTP Assurance Level 10, 446 Collins Street Melbourne VIC 3000
Stock exchange listing	Biome Australia Limited shares are listed on the Australian Securities Exchange (ASX code: BIO)
Website	https://biomeaustralia.com/

Biome Australia Limited**Contents****31 December 2021**

Directors' report	3
Auditor's independence declaration	5
Statement of profit or loss and other comprehensive income	6
Statement of financial position	7
Statement of changes in equity	8
Statement of cash flows	9
Notes to the financial statements	10
Directors' declaration	15
Independent auditor's review report to the members of Biome Australia Limited	16

Biome Australia Limited
Directors' report
31 December 2021

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Biome Australia Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2021.

The company was incorporated on 6 July 2018 and is the holding company for its fully owned subsidiaries Biome Australia Trading Pty Ltd and Biome Australia IP Pty Ltd, both incorporated on 24 September 2018 as detailed within the company's Prospectus dated 19 October 2021 and lodged with ASIC the same day. The comparable for the previous corresponding period (PCP) for the six months to, and as at, 31 December 2020 represents the results of Biome Australia and its wholly-owned subsidiaries.

Directors

The following persons were directors of Biome Australia Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mr Ilario Thomas Faenza - Non-executive Director (appointed 18 August 2020)
Mr Blair William Brabin Vega Norfolk - Managing Director (appointed 6 July 2018)
Ms Dominique Gayle Fisher - Independent Non-executive Director (appointed 12 August 2021)
Dr Jaroslav Haman Boublik - Non-executive Director (resigned 19 October 2021)
Douglas Chee Yong Loh - Executive Director (resigned 19 October 2021)

Principal activities

The principal activities of the Group during the financial half-year were developing, manufacturing and distributing innovative evidence-based products linking the gut and human health through the Group owned brands:

- Activated Nutrients, a range of completely organic, plant-based, all in-one nutritional products;
- Activated Probiotics, a first-of-its-kind range of clinically-backed precision probiotics; and
- AXP, a certified range of performance products for athletes.

Review of operations

Financial Performance

During the half year period, the Company experienced strong sales growth with revenue increasing by 98.2% to \$1,802,611 compared to the previous corresponding period (1H21 \$909,561). The strong sales growth has been driven primarily by Biome's Activated Probiotics, live biotherapeutics (probiotics).

Retail pharmacy partner, Terry White Chemmart and pharmacy wholesaler Symbion, both reported that Biome's Activated Probiotics is the number one growth brand in the professional vitamin category within their networks for the 12 months to October 2021. The sales trajectory has also benefitted from the progressive easing of the COVID-19 lockdown restrictions throughout Australia and the consequential return of active field sales.

The loss for the consolidated entity after providing for income tax amounted to \$2,479,914 (31 December 2020: \$3,314,622). Sales and marketing costs increased by \$142,152 to \$1,879,668 as a result of increased expenditure on promoting the Company's products.

During the half year the Company strengthened its product portfolio through the launch of Biome Eczema Probiotic and Biome Her Probiotic, opening up new patient customer segments. Feedback from customers (health professionals) has been favourable, reporting positive patient outcomes and improvements in both mild eczema and female genitourinary health concerns following use of Biome Eczema Probiotic and Biome Her Probiotic, respectively.

Biome's largest distribution channel continues to be community pharmacy. Recent launches into the health food and practitioner channels with distributors, Osborne Health, Renner Health, Ariya and Vital.ly have supported growth in this new channel. Independent health practitioners now represent more than 20% of Biome's total sales.

Financial Position

During the financial year, the Company raised \$8 million before capital raising costs through an initial public offering and had \$7,743,968 in cash as at 31 December 2021.

The net assets of the Company increased by \$7005,585 to \$8,585,713 as at 31 December 2021 which was a result of the Company's IPO and capital raising.

Biome Australia Limited
Directors' report
31 December 2021

Significant changes in the state of affairs

During the half year period the Company lodged a Prospectus in relation to a capital raising for the issue of 40,000,000 fully paid ordinary shares with an issue price of \$0.20 (20 cents) per share raising \$8 million before costs. The Company completed its capital raising in November 2021 and listed on the Australian Stock Exchange (ASX) on 30 November 2021.

During the half year period and in accordance with the terms of a capital raising mandate with the Company's IPO lead manager, the Company issued a total of 4,262,808 unlisted options with the following terms:

- 2,131,404 options have been issued with an exercise price of \$0.30 exercisable for a period of three years from the date of issue; and
- 2,131,404 options have been issued with an exercise price of \$0.40 exercisable for a period of three years from the date of issue.

During the half year period the Company issued 4,682,156 (post-consolidated basis) performance rights and a total of 16,674,908 (post consolidated) fully paid ordinary shares were issued following the conversion of 16,674,908 (post-consolidated) performance rights. There are nil performance rights on issue at 31 December 2021.

On 18 October 2021 the Company undertook a restructure of its share capital whereby 342,088,475 shares were consolidated into 148,733,950 ordinary shares.

There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Ilario Faenza
Chairman

25 February 2022

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIOME AUSTRALIA LIMITED**

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2021 there have been:

- (i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- (ii) No contraventions of any applicable code of professional conduct in relation to the review.

JTP Assurance

JTP ASSURANCE
Chartered Accountants

W. Tarrant

WAYNE TARRANT
Partner

Signed at Melbourne this 25th day of February 2022

Biome Australia Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2021

		Consolidated	
	Note	31 December 2021	31 December 2020
		\$	\$
Revenue			
Sales revenue	5	1,802,611	909,561
Cost of goods sold		<u>(762,087)</u>	<u>(418,075)</u>
Gross profit		<u>1,040,524</u>	<u>491,486</u>
Other income	6	256,626	160,201
Expenses			
Sales and marketing expenses		(1,879,668)	(1,737,516)
Corporate and administrative expenses		(1,496,456)	(1,814,733)
Occupancy costs		(57,159)	(57,557)
Finance expenses		(26,642)	(27,077)
Depreciation and amortisation expense		(21,370)	(34,055)
Other expenses		<u>(295,769)</u>	<u>(295,371)</u>
Loss before income tax expense		(2,479,914)	(3,314,622)
Income tax expense		<u>-</u>	<u>-</u>
Loss after income tax expense for the half-year attributable to the owners of Biome Australia Limited		(2,479,914)	(3,314,622)
Other comprehensive income for the half-year, net of tax		<u>-</u>	<u>-</u>
Total comprehensive income for the half-year attributable to the owners of Biome Australia Limited		<u><u>(2,479,914)</u></u>	<u><u>(3,314,622)</u></u>

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of financial position
As at 31 December 2021

		Consolidated	
		31 December	
	Note	2021	30 June 2021
		\$	\$
Assets			
Current assets			
Cash and cash equivalents		7,743,968	609,978
Trade and other receivables		542,354	738,214
Inventories	7	979,632	1,020,895
GST tax receivable		106,056	609
Other assets	8	119,858	24,634
Total current assets		<u>9,491,868</u>	<u>2,394,330</u>
Non-current assets			
Property, plant and equipment		59,704	105,593
Right-of-use assets	9	482,019	-
Total non-current assets		<u>541,723</u>	<u>105,593</u>
Total assets		<u>10,033,591</u>	<u>2,499,923</u>
Liabilities			
Current liabilities			
Trade and other payables		822,152	705,697
Borrowings		-	15,735
Lease liabilities	10	69,700	-
Short-term provisions - employee entitlements		133,597	133,598
Other		-	83
Total current liabilities		<u>1,025,449</u>	<u>855,113</u>
Non-current liabilities			
Borrowings		-	64,682
Lease liabilities	11	422,429	-
Total non-current liabilities		<u>422,429</u>	<u>64,682</u>
Total liabilities		<u>1,447,878</u>	<u>919,795</u>
Net assets		<u>8,585,713</u>	<u>1,580,128</u>
Equity			
Issued capital	12	20,639,835	9,830,488
Reserves	13	474,879	1,643,175
Accumulated losses		<u>(12,529,001)</u>	<u>(9,893,535)</u>
Total equity		<u>8,585,713</u>	<u>1,580,128</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of changes in equity
For the half-year ended 31 December 2021

	Ordinary capital \$	Subscribed share capital \$	Share based payment & option reserve \$	Accumulated losses \$	Total equity \$
Consolidated					
Balance at 1 July 2020	5,877,185	72,500	52,200	(5,052,349)	949,536
Loss after income tax expense for the half-year	-	-	-	(3,314,622)	(3,314,622)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(3,314,622)	(3,314,622)
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs	1,363,966	-	-	-	1,363,966
Share-based payments	-	-	1,710,000	-	1,710,000
Transfer of issued capital	72,500	(72,500)	-	-	-
Balance at 31 December 2020	<u>7,313,651</u>	<u>-</u>	<u>1,762,200</u>	<u>(8,366,971)</u>	<u>708,880</u>
	Ordinary shares \$	Option reserve \$	Performance rights \$	Accumulated losses \$	Total equity \$
Consolidated					
Balance at 1 July 2021	9,830,488	83,205	1,559,970	(9,893,535)	1,580,128
Loss after income tax expense for the half-year	-	-	-	(2,479,914)	(2,479,914)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(2,479,914)	(2,479,914)
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs (note 12)	8,508,210	-	-	-	8,508,210
Share-based payments (note 16)	-	405,734	-	-	405,734
Exercise of performance rights (notes 11 & 12)	2,301,137	-	(2,301,137)	-	-
Issue of performance rights	-	-	585,615	-	585,615
Cancellation of options	-	(14,060)	-	-	(14,060)
Transfer to accumulated losses	-	-	155,552	(155,552)	-
Balance at 31 December 2021	<u>20,639,835</u>	<u>474,879</u>	<u>-</u>	<u>(12,529,001)</u>	<u>8,585,713</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

Biome Australia Limited
Statement of cash flows
For the half-year ended 31 December 2021

		Consolidated	
	Note	31 December 2021	31 December 2020
		\$	\$
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		1,998,471	740,656
Payments to suppliers and employees (inclusive of GST)		(3,962,803)	(1,229,921)
R&D tax refund		223,275	-
Other government grants received		33,000	-
Interest received		351	-
		<u> </u>	<u> </u>
Net cash used in operating activities		(1,707,706)	(489,265)
Cash flows from investing activities			
Payments for property, plant and equipment		-	(57,125)
Proceeds from disposal of property, plant and equipment		24,519	-
		<u> </u>	<u> </u>
Net cash from/(used in) investing activities		24,519	(57,125)
Cash flows from financing activities			
Proceeds from issue of shares	12	9,678,651	1,083,097
Share issue transaction costs		(764,707)	-
Repayment of borrowings		(96,767)	(389,249)
		<u> </u>	<u> </u>
Net cash from financing activities		8,817,177	693,848
Net increase in cash and cash equivalents		7,133,990	147,458
Cash and cash equivalents at the beginning of the financial half-year		609,978	448,867
		<u> </u>	<u> </u>
Cash and cash equivalents at the end of the financial half-year		<u><u>7,743,968</u></u>	<u><u>596,325</u></u>

The above statement of cash flows should be read in conjunction with the accompanying notes

Biome Australia Limited
Notes to the financial statements
31 December 2021

Note 1. General information

The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Biome Australia Limited's functional and presentation currency.

Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office	Principal place of business
16 Dover Street Cremorne Victoria 3121	16 Dover Street Cremorne Victoria 3121

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 25 February 2022.

Note 2. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2021 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Note 3. Critical accounting judgements, estimates and assumptions (continued)

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Note 4. Operating segments

Identification of reportable operating segments

The company is organised into one operating segment: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. This operating segment is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Note 5. Sales revenue

	Consolidated	
	31 December 2021	31 December 2020
	\$	\$
Sales - Domestic	1,667,901	909,561
Sales - International	134,710	-
	<u>1,802,611</u>	<u>909,561</u>

Note 6. Other income

	Consolidated	
	31 December 2021	31 December 2020
	\$	\$
Government grants	33,000	124,000
Interest	351	201
R & D rebate	223,275	36,000
Other income	<u>256,626</u>	<u>160,201</u>

Note 7. Current assets - inventories

	Consolidated	
	31 December 2021	30 June 2021
	\$	\$
Finished goods - at cost	1,167,810	1,249,483
Less: Provision for impairment and samples	(188,178)	(228,588)
	<u>979,632</u>	<u>1,020,895</u>

Biome Australia Limited
Notes to the financial statements
31 December 2021

Note 8. Current assets - Other assets

	Consolidated	
	31 December	30 June 2021
	2021	2021
	\$	\$
Prepayments	64,782	-
Bank Guarantee (bond)	54,884	24,634
Other current assets	192	-
	<u>119,858</u>	<u>24,634</u>

Note 9. Non-current assets - right-of-use assets

	Consolidated	
	31 December	30 June 2021
	2021	2021
	\$	\$
Right-of-use-assets	490,189	-
Less: Accumulated depreciation	(8,170)	-
	<u>482,019</u>	<u>-</u>

Note 10. Current liabilities - lease liabilities

	Consolidated	
	31 December	30 June 2021
	2021	2021
	\$	\$
Lease liability	<u>69,700</u>	<u>-</u>

Note 11. Non-current liabilities - lease liabilities

	Consolidated	
	31 December	30 June 2021
	2021	2021
	\$	\$
Lease liability	<u>422,429</u>	<u>-</u>

Note 12. Equity - issued capital

	Consolidated			
	31 December	30 June 2021	31 December	30 June 2021
	2021	2021	2021	2021
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>199,909,857</u>	<u>301,464,273</u>	<u>20,639,835</u>	<u>9,830,488</u>

Biome Australia Limited
Notes to the financial statements
31 December 2021

Note 12. Equity - issued capital (continued)

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance	1 July 2021	301,464,273		9,830,488
Issue of shares	19 July to 31 August 2021	27,976,494	\$0.06	1,678,651
Exercise of performance rights	3 & 18 August 2021	12,647,708	\$0.06	758,862
Consolidation of capital on a 2.3 : 1 basis	18 October 2021	(193,354,525)	\$0.00	-
Issue of shares through initial public offering	24 November 2021	40,000,000	\$0.20	8,000,000
Exercise of performance rights	24 November 2021	11,175,907	\$0.13	1,542,275
Capital raising costs		-	\$0.00	(1,170,441)
Balance	31 December 2021	<u>199,909,857</u>		<u>20,639,835</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 13. Equity - reserves

	Consolidated	
	31 December 2021	30 June 2021
	\$	\$
Share-based payments reserve	-	1,559,970
Share option reserve	474,879	83,205
	<u>474,879</u>	<u>1,643,175</u>

Movements in reserves

Movements in each class of reserve during the current financial half-year are set out below:

Consolidated	Share based payments \$	Share option \$	Total \$
Balance at 1 July 2021	1,559,970	83,205	1,643,175
Transfer to accumulated losses	155,552	-	155,552
Transfer to equity	(2,301,138)	-	(2,301,138)
Share based payment expense	585,616	405,734	991,350
Cancellation of options	-	(14,060)	(14,060)
Balance at 31 December 2021	<u>-</u>	<u>474,879</u>	<u>474,879</u>

Note 14. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Biome Australia Limited
Notes to the financial statements
31 December 2021

Note 15. Events after the reporting period

No matter or circumstance has arisen since 31 December 2021 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 16. Share-based payments

During the half year period and in accordance with the terms of a capital raising mandate with the Company's IPO lead manager, the Company issued a total of 4,262,808 unlisted options with the following terms:

- 2,131,404 options have been issued with an exercise price of \$0.30 exercisable for a period of three years from the date of issue; and
- 2,131,404 options have been issued with an exercise price of \$0.40 exercisable for a period of three years from the date of issue.

A share based payment amount of \$405,734 has been recorded as a capital raising cost in relation to the issue of options.

Set out below are summaries of options granted under the capital raising mandate:

31 December
2021

Grant date	Expiry date	Exercise price	Balance at the start of the half-year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the half-year
24/11/2021	24/11/2024	\$0.30	-	2,131,404	-	-	2,131,404
24/11/2021	24/11/2025	\$0.40	-	2,131,404	-	-	2,131,404
			-	4,262,808	-	-	4,262,808

For the options granted during the current financial half-year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
24/11/2021	24/11/2024	\$0.20	\$0.30	88.16%	-	0.21%	\$0.092
24/11/2021	24/11/2025	\$0.20	\$0.40	88.16%	-	0.21%	\$0.097

Biome Australia Limited
Directors' declaration
31 December 2021

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2021 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



Mr Ilario Faenza
Chairman

25 February 2022

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF BIOME AUSTRALIA LIMITED
ABN 51 627 364 014**Report on the Half-year Financial Report**

We have reviewed the accompanying half-year financial report of Biome Australia Limited, which comprises the consolidated condensed statement of financial position as at 31 December 2021, the consolidated condensed statement of profit or loss, the consolidated condensed statement of comprehensive income, the consolidated condensed statement of changes in equity and the consolidated condensed statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Half-year Financial Report

The directors of Biome Australia Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of Biome Australia Limited's financial position as at 31 December 2021 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Biome Australia Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Biome Australia Limited is not in accordance with the Corporations Act 2001, including:

- (i) giving a true and fair view of Biome Australia Limited 's financial position as at 31 December 2021 and of its performance for the half-year ended on that date; and
- (ii) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

JTP Assurance

JTP ASSURANCE
Chartered Accountants

W. Tarrant

WAYNE TARRANT
Partner

Signed at Melbourne this 25th day of February 2022